Merocarb (Meropenem Anhydrous)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, preventing the cross‑linking of peptidoglycan strands. This leads to loss of cell‑wall integrity, osmotic lysis, and rapid bacterial death, covering a broad range of Gram‑positive, Gram‑negative, and anaerobic organisms.

The dosage of Merocarb is determined by the prescribing clinician based on infection severity, patient weight, renal function, and local antimicrobial guidelines. Healthcare professionals calculate the appropriate intravenous infusion rate and duration for each individual case.

Merocarb is classified as pregnancy category B, indicating no evidence of fetal risk in animal studies, but human data are limited. It should be used only if the potential benefit justifies any potential risk. Limited data are available for breastfeeding; a risk‑benefit assessment is recommended.

To order Merocarb, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and import documentation.

Merocarb (meropenem) shares the broad‑spectrum activity of other carbapenems such as imipenem and ertapenem but offers enhanced stability against many β‑lactamases and a slightly broader anaerobic coverage. Choice among carbapenems depends on local resistance patterns, dosing convenience, and specific patient factors.

Merocarb must be stored at 2‑8 °C in a refrigerator, protected from light. The vial should remain in its original packaging, should not be frozen, and must be gently handled to avoid agitation that could affect solution integrity.

Merocarb is supplied as an injectable solution for intravenous infusion. It is administered by a healthcare professional through a peripheral or central line, typically over a 15‑30 minute infusion, with dosing adjusted for renal function and infection severity.

The most serious risks include the potential for seizures, especially in patients with renal impairment or pre‑existing CNS disorders, and severe hypersensitivity reactions such as anaphylaxis. Clinicians should also monitor for Clostridioides difficile‑associated colitis, which can be life‑threatening.

Merocarb should be avoided in patients with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is advised for patients with a history of seizures, severe renal impairment, or those receiving valproic acid, unless benefits outweigh risks.